Current Headlines

  1. DNDi and Atomwise Collaborate To Advance Drug Development Using AI For Neglected Diseases
    4/16/2019

    Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, recently announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease

  2. Gilead And insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis
    4/16/2019

    Gilead Sciences Inc. and insitro announced recently that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

  3. Aquestive Therapeutics Announces U.S. Food And Drug Administration (FDA) Acceptance Of New Drug Application For Riluzole Oral Film For Treatment Of ALS
    4/16/2019

    Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for the investigational product riluzole oral film (ROF), which the Company intends to market under the brand name Exservan

  4. Idronoxil Confirmed As Noxopharm’s New Immuno-Oncology Drug Candidate
    4/16/2019

    Noxopharm (ASX: NOX) releases data from the first series of pre-clinical studies confirming that idronoxil (IDX), the active ingredient in the Company’s anti-cancer drug candidate, Veyonda®, activates the immune system

  5. Viracta Receives Orphan Drug Designation From The US FDA For Its Lead Epigenetic Drug Candidate Nanatinostat For EBV-Associated Cancers
    4/16/2019

    Viracta Therapeutics, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. The therapeutic approach is being investigated in a Phase 1b/2 clinical trial of Epstein Barr Virus (EBV)-associated lymphomas, including the ODD granted subtypes.

  6. Pulmatrix And Cipla Technologies LLC Enter Into Definitive Agreement For The Development And Commercialization Of Pulmazole™
    4/15/2019

    Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, and Cipla Technologies LLC ("Cip Tec"), a subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; along with its subsidiaries, affiliates and joint ventures, hereafter together referred to as "Cipla") today announced their entry into a Definitive Agreement for the co-development and commercialization of Pulmazole™ (PUR1900) – an inhaled iSPERSE™ formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma

  7. uniQure Receives FDA Fast Track Designation For AMT-130 Gene Therapy For The Treatment Of Huntington’s Disease
    4/12/2019

    uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease

  8. Immuron Receives U.S. Patent On Drug Composition To Treat Clostridium Difficile
    4/11/2019

    Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immuno-therapeutics for the treatment of gut mediated diseases, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) for a method to treat Clostridium difficile infections. The patent (USPTO No. 10144775) entitled “Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease” describes a targeted drug composition comprising an enriched, hyperimmune polyclonal antibody preparation of bovine colostrum for use in treating C. difficile, a bacterium that causes life threatening diarrhea

  9. In-orbit Manufacturing And Drug Development Research Among U.S. National Lab-sponsored Payloads Destined For The Space Station
    4/11/2019

    The International Space Station (ISS) U.S. National Laboratory is managing 13 separate payloads launching to the orbiting laboratory to advance basic and applied research in several disciplines

  10. Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer
    4/11/2019

    Evotec SE and Indivumed GmbH announced recently that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”)